Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 1/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 1/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 1/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2849537 | 0.92 | MAPK14 (0.86) | MAPK14MAPK13MAPK12MAPK11MAPK10 | |
| SCHEMBL2851382 | 0.91 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11MAPK10 | |
| SCHEMBL2847870 | 0.90 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11MAPK10 | |
| SCHEMBL2846586 | 0.88 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11MAPK10 | |
| SCHEMBL2847240 | 0.88 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11MAPK10 | |
| SCHEMBL2843750 | 0.87 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11MAPK10 | |
| SCHEMBL2849538 | 0.85 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3222841 | 0.81 | MAPK14 (0.86) | MAPK14MAPK13MAPK12MAPK11MAPK10 | |
| SCHEMBL3109130 | 0.81 | MAPK14 (0.82) | MAPK14MAPK13MAPK12MAPK11MAPK10 | |
| SCHEMBL2851739 | 0.81 | MAPK14 (0.82) | MAPK14MAPK13MAPK12MAPK11MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273833-A1 | 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | MERCKLE GMBH (DE) | 2010-10-28 | — | — | US | disclosed |
| EP-1853581-B1 | 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | MERCKLE GMBH (DE) | 2010-06-02 | — | — | EP | disclosed |
| US-20100069436-A1 | IMIDAZOLE COMPOUNDS HAVING AN ANTIINFLAMMATORY EFFECT | Merckle (DE) | 2010-03-18 | — | — | US | disclosed |
| EP-2054404-A1 | IMIDAZOLE COMPOUNDS HAVING AN ANTIINFLAMMATORY EFFECT | MERCKLE GMBH (DE) | 2009-05-06 | — | — | EP | disclosed |
| EP-1894925-A1 | Imidazole compounds having an antiinflammatory effect | MERCKLE GMBH (DE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2008023066-A1 | IMIDAZOLE COMPOUNDS HAVING AN ANTIINFLAMMATORY EFFECT | MERCKLE GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
| EP-1853581-A1 | 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | MERCKLE GMBH (DE) | 2007-11-14 | — | — | EP | disclosed |
| US-7253191-B2 | 2-thio-substituted imidazole derivatives and the use thereof in the pharmaceutical industry | MERCKLE GMBH (DE) | 2007-08-07 | — | — | US | disclosed |
| WO-2006089798-A1 | 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | MERCKLE GMBH (DE) | 2006-08-31 | — | — | WO | disclosed |
| EP-1362045-B1 | 2-THIO-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THE USE THEREOF IN THE PHARMACEUTICAL INDUSTRY | MERCKLE GMBH (DE) | 2004-11-17 | — | — | EP | disclosed |
| US-20040116416-A1 | 2-thio-substituted imidazole derivatives and the use thereof in the pharmaceutical industry | MERCKLE GMBH (DE) | 2004-06-17 | — | — | US | disclosed |
| EP-1362045-A2 | 2-THIO-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THE USE THEREOF IN THE PHARMACEUTICAL INDUSTRY | MERCKLE GMBH (DE) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002066458-A2 | 2-THIO-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THE USE THEREOF IN THE PHARMACEUTICAL INDUSTRY | MERCKLE GMBH (DE) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069436-A1 | IMIDAZOLE COMPOUNDS HAVING AN ANTIINFLAMMATORY EFFECT | MIF, TNF, IL1B | MAPK14 2368/4885MAPK13 2173/4885MAPK12 1839/4885 |
| US-20100273833-A1 | 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | IL2, IL2RA, IL1B | MAPK14 1604/4885MAPK13 1854/4885MAPK12 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.